Latest Trustworthy News from Dr. Mercola - delivered straight to your inbox!
My New Book is Now A Best Seller | Order Now My New Book is Now A Best Seller | Order Now

New Risks for Pepcid

  • January 20, 2005

With Merck's failed bid to secure over-the-counter (OTC) status for Mevachor still fresh on my mind, a FDA report this week about labeling changes in drugs caught my attention. At the bottom of the report was a brief mention of the H2-receptor antagonist, Famotidine, better known by its OTC label Pepcid. The FDA will now require Pepcid to include for the following warning on its label: "Famotidine should not be used in patients experiencing difficult or painful swallowing, vomiting with...